Home
News
Interviews
Companies
Videos
Markets
Subscribe
The
Latest
The Latest
News
Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario
News
Novamind Launches Group Psychedelic Treatment for Frontline Workers
News
Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022
News
Optimi Health Acquires Extensive Catalog of Psychedelic and Functional Mushroom Genetics
More Articles
FEATURED
Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment
News
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal
News
Ceruvia Lifesciences Submits FDA Investigational New Drug Application for Psilocybin Obsessive-Compulsive Disorder Program
Trending
#
Spotlight
Daniel Carcillo | Founder and CEO, Wesana Health
#
Spotlight
Aaron Bartlone, Chief Operating Officer | Cybin
#
Spotlight
Dr. Albert Garcia-Romeu | Johns Hopkins University School of Medicine
#
News
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
#
News
Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment
Companies
#
Cybin Inc.
NEO
NASDAQ
CSE
TSXV
Private Company
Non-Profit
#
Numinus
NEO
NASDAQ
CSE
TSXV
Private Company
Non-Profit
#
Mind Medicine (MindMed)
NEO
NASDAQ
CSE
TSXV
Private Company
Non-Profit
#
Wesana Health
NEO
NASDAQ
CSE
TSXV
Private Company
Non-Profit
#
Tryp Therapeutics
NEO
NASDAQ
CSE
TSXV
Private Company
Non-Profit
